CARLSBAD, Calif.--(BUSINESS WIRE)--The University of California, San Diego, The Salk Institute for Biological Studies and Life Technologies Corporation (NASDAQ: LIFE) today announced the initiation of studies which may lead to the future development of cell transplant therapy for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. Currently, there is only one FDA-approved pharmaceutical addressing this lethal disease, which affects approximately 30,000 people in the United States.
